Phase 1b randomised placebo-controlled trial in 32 people with ART-suppressed HIV-1: single doses of budigalimab (10 or 20 mg SC, 10 mg IV) caused no grade 4 or treatment-related serious AEs; one reversible grade 2 immune-related AE; PD-1 saturation was 95% or more in most.
RCTn = 32
Vaidya et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load